Differentiation and Function of Follicular CD8 T Cells During Human Immunodeficiency Virus Infection

The combination antiretroviral therapeutic (cART) regime effectively suppresses human immunodeficiency virus (HIV) replication and prevents progression to acquired immunodeficiency diseases. However, cART is not a cure, and viral rebound will occur immediately after treatment is interrupted largely...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 9; p. 1095
Main Authors Xiao, Minglu, Chen, Xiangyu, He, Ran, Ye, Lilin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 22.05.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The combination antiretroviral therapeutic (cART) regime effectively suppresses human immunodeficiency virus (HIV) replication and prevents progression to acquired immunodeficiency diseases. However, cART is not a cure, and viral rebound will occur immediately after treatment is interrupted largely due to the long-term presence of an HIV reservoir that is composed of latently infected target cells that maintain a quiescent state or persistently produce infectious viruses. CD4 T cells that reside in B-cell follicles within lymphoid tissues, called follicular helper T cells (TFH), have been identified as a major HIV reservoir. Due to their specialized anatomical structure, HIV-specific CD8 T cells are largely insulated from this TFH reservoir. It is increasingly clear that the elimination of TFH reservoirs is a key step toward a functional cure for HIV infection. Recently, several studies have suggested that a fraction of HIV-specific CD8 T cells can differentiate into a CXCR5-expressing subset, which are able to migrate into B-cell follicles and inhibit viral replication. In this review, we discuss the differentiation and functions of this newly identified CD8 T-cell subset and propose potential strategies for purging TFH HIV reservoirs by utilizing this unique population.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Specialty section: This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
Reviewed by: Elizabeth Connick, University of Arizona, United States; Amitinder Kaur, Tulane University, United States; Stuart G. Tangye, Garvan Institute of Medical Research, Australia
Edited by: Vijayakumar Velu, Emory University, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2018.01095